ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Lunsumio 1 mg concentrate for solution for infusion
Lunsumio 30 mg concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Lunsumio 1 mg concentrate for solution for infusion
Each vial contains 1 mg of mosunetuzumab in 1 mL at a concentration of 1 mg/mL.

Lunsumio 30 mg concentrate for solution for infusion
Each vial contains 30 mg of mosunetuzumab in 30 mL at a concentration of 1 mg/mL.

Mosunetuzumab is a full-length, humanized anti-CD20/CD3 immunoglobulin (Ig)G1 isotype that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Concentrate for solution for infusion.
Clear, colourless liquid, pH 5.8 and osmolality of 240-333 mOsm/kg.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

4.2 Posology and method of administration

Lunsumio must only be administered under the supervision of a healthcare professional qualified in the use of anti-cancer therapies, in a setting with appropriate medical support to manage severe reactions such as cytokine release syndrome (CRS) (see section 4.4).

Posology

Prophylaxis and premedication

Lunsumio should be administered to well-hydrated patients.

Table 1 provides details on recommended premedication for CRS and infusion related reactions.
### Table 1  Premedication to be administered to patients prior to Lunsumio infusion

<table>
<thead>
<tr>
<th>Patients requiring premedication</th>
<th>Premedication</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycles 1 and 2: all patients</td>
<td>Intravenous corticosteroids: dexamethasone 20 mg or methylprednisolone 80 mg</td>
<td>Complete at least 1 hour prior to Lunsumio infusion</td>
</tr>
<tr>
<td>Cycles 3 and beyond: patients who experienced any grade CRS with previous dose</td>
<td>Anti-histamine: 50-100 mg diphenhydramine hydrochloride or equivalent oral or intravenous anti-histamine</td>
<td>At least 30 minutes prior to Lunsumio infusion</td>
</tr>
<tr>
<td></td>
<td>Anti-pyretic: 500-1000 mg paracetamol</td>
<td></td>
</tr>
</tbody>
</table>

The recommended dose of Lunsumio for each 21 day-cycle is detailed in Table 2.

### Table 2  Dose of Lunsumio for patients with relapsed or refractory follicular lymphoma

<table>
<thead>
<tr>
<th>Day of treatment</th>
<th>Dose of Lunsumio</th>
<th>Rate of infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1</td>
<td>Day 1</td>
<td>1 mg</td>
</tr>
<tr>
<td></td>
<td>Day 8</td>
<td>2 mg</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>60 mg</td>
</tr>
<tr>
<td>Cycle 2</td>
<td>Day 1</td>
<td>60 mg</td>
</tr>
<tr>
<td>Cycles 3 and beyond</td>
<td>Day 1</td>
<td>30 mg</td>
</tr>
</tbody>
</table>

**Duration of treatment**

Lunsumio should be administered for 8 cycles, unless a patient experiences unacceptable toxicity or disease progression.

For patients who achieve a complete response, no further treatment beyond 8 cycles is required. For patients who achieve a partial response or have stable disease in response to treatment with Lunsumio after 8 cycles, an additional 9 cycles of treatment (17 cycles total) should be administered, unless a patient experiences unacceptable toxicity or disease progression.

**Delayed or missed dose**

If any dose in cycle 1 is delayed for > 7 days, the previous tolerated dose should be repeated prior to resuming the planned treatment schedule.

If a dose interruption occurs between Cycles 1 and 2 that results in a treatment-free interval of ≥ 6 weeks, Lunsumio should be administered at 1 mg on Day 1, 2 mg on Day 8, then resume the planned Cycle 2 treatment of 60 mg on Day 15.

If a dose interruption occurs that results in a treatment-free interval of ≥ 6 weeks between any Cycles in Cycle 3 onwards, Lunsumio should be administered at 1 mg on Day 1, 2 mg on Day 8, then resume the planned treatment schedule of 30 mg on Day 15.

**Dose modification**

Patients who experience grade 3 or 4 reactions (e.g. serious infection, tumour flare, tumour lysis syndrome) should have treatment temporarily withheld until symptoms are resolved (see section 4.4).

CRS should be identified based on clinical presentation (see section 4.4). Patients should be evaluated and treated for, other causes of fever, hypoxia, and hypotension, such as infections/sepsis. Infusion related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. If CRS or IRR
is suspected, patients should be managed according to the recommendations in Table 3.

Table 3  CRS grading\textsuperscript{1} and management

<table>
<thead>
<tr>
<th>CRS grade</th>
<th>CRS management\textsuperscript{2}</th>
<th>Next scheduled infusion of Lunsumio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grade 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever $\geq$ 38°C</td>
<td>If CRS occurs during infusion:</td>
<td>The symptoms should be resolved for at least 72 hours prior to next infusion</td>
</tr>
<tr>
<td></td>
<td>• The infusion should be interrupted and symptoms treated</td>
<td>The patient should be monitored more frequently</td>
</tr>
<tr>
<td></td>
<td>• The infusion should be re-started at the same rate once the symptoms resolve</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• If symptoms recur with re-administration, the current infusion should be discontinued</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If CRS occurs post-infusion:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The symptoms should be treated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If CRS lasts $&gt; 48$ hours after symptomatic management:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dexamethasone\textsuperscript{3} and/or tocilizumab\textsuperscript{4,5} should be considered</td>
<td></td>
</tr>
<tr>
<td><strong>Grade 2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever $\geq$ 38°C and/or hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen\textsuperscript{6} by nasal cannula or blow-by</td>
<td>If CRS occurs during infusion:</td>
<td>The symptoms should be resolved for at least 72 hours prior to next infusion</td>
</tr>
<tr>
<td></td>
<td>• The infusion should be interrupted and symptoms treated</td>
<td>Premedication should be maximized as appropriate\textsuperscript{7}</td>
</tr>
<tr>
<td></td>
<td>• The infusion should be re-started at 50% the rate once the symptoms resolve</td>
<td>Consideration should be given to administration of the next infusion 50% rate, with more frequent monitoring of the patient</td>
</tr>
<tr>
<td></td>
<td>• If symptoms recur with re-administration, the current infusion should be discontinued</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If CRS occurs post-infusion:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The symptoms should be treated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If no improvement occurs after symptomatic management:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dexamethasone\textsuperscript{3} and/or tocilizumab\textsuperscript{4,5} should be considered</td>
<td></td>
</tr>
<tr>
<td><strong>Grade 3</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever $\geq$ 38°C and/or hypotension requiring a vasopressor (with or without vasopressin) and/or hypoxia requiring high flow oxygen\textsuperscript{8} by nasal cannula, face</td>
<td>If CRS occurs during infusion:</td>
<td>The symptoms should be resolved for at least 72 hours prior to next infusion</td>
</tr>
<tr>
<td></td>
<td>• The current infusion should be discontinued</td>
<td>Patients should be hospitalized for the next infusion</td>
</tr>
<tr>
<td></td>
<td>• The symptoms should be treated</td>
<td>Premedication should be maximized as appropriate\textsuperscript{7}</td>
</tr>
<tr>
<td></td>
<td>• Dexamethasone\textsuperscript{3} and tocilizumab\textsuperscript{4,5} should be administered</td>
<td>The next infusion should be administered at a 50% rate</td>
</tr>
</tbody>
</table>
If CRS is refractory to dexamethasone and tocilizumab:
- Alternative immunosuppressants\(^9\) and methylprednisolone 1 000 mg/day intravenously should be administered until clinical improvement

<table>
<thead>
<tr>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever ≥ 38°C and/or hypotension requiring multiple vasoressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation)</td>
</tr>
</tbody>
</table>

If CRS occurs during or post-infusion:
- Treatment with Lunsumio should be permanently discontinued
- The symptoms should be treated
- Dexamethasone\(^3\) and tocilizumab\(^4, 5\) should be administered

If CRS is refractory to dexamethasone and tocilizumab:
- Alternative immunosuppressants\(^9\) and methylprednisolone 1 000 mg/day intravenously should be administered until clinical improvement

1 ASTCT = American Society for Transplant and Cellular Therapy. Premedication may mask fever, therefore if clinical presentation is consistent with CRS, please follow these management guidelines.
2 If CRS is refractory to management, consider other causes including hemophagocytic lymphohistiocytosis
3 Dexamethasone should be administered at 10 mg intravenously every 6 hours (or equivalent) until clinical improvement
4 In study GO29781, tocilizumab was administered intravenously at a dose of 8 mg/kg (not to exceed 800 mg per infusion), as needed for CRS management
5 If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, a second dose of intravenous tocilizumab 8 mg/kg may be administered at least 8 hours apart (maximum 2 doses per CRS event). Within each time period of 6 weeks of Lunsumio treatment, the total amount of tocilizumab doses should not exceed 3 doses
6 Low-flow oxygen is defined as oxygen delivered at < 6 L/minute.
7 Refer to Table 1 for additional information
8 High-flow oxygen is defined as oxygen delivered at ≥ 6 L/minute
9 Riegler L et al. (2019)

**Special populations**

**Elderly**

No dose adjustment of Lunsumio is required in patients ≥ 65 years of age (see section 5.2).

**Renal impairment**

Lunsumio has not been studied in patients with severe renal impairment. Dose adjustments are not considered necessary in patients with mild to moderate renal impairment based on pharmacokinetics (see section 5.2).
Hepatic impairment

Lunsumio has not been studied in patients with hepatic impairment. Dose adjustments are not considered necessary based on pharmacokinetics (see section 5.2).

Paediatric population

The safety and efficacy of Lunsumio in children below 18 years of age have not yet been established.

Method of administration

Lunsumio is for intravenous use only.

Lunsumio must be diluted using aseptic technique under the supervision of a healthcare professional. It should be administered as an intravenous infusion through a dedicated infusion line. Do not use an in-line filter to administer Lunsumio. Drip chamber filters can be used to administer Lunsumio.

The first cycle of Lunsumio should be administered over a minimum of 4 hours as intravenous infusion. If the infusions are well-tolerated in cycle 1, the subsequent cycles may be administered over a 2-hours infusion.

Lunsumio must not be administered as intravenous push or bolus.

For instructions on dilution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded.

Cytokine Release Syndrome (CRS)

CRS, including life-threatening reactions, have occurred in patients receiving Lunsumio (see section 4.8). Signs and symptoms included pyrexia, chills, hypotension, tachycardia, hypoxia, and headache. Infusion related reactions may be clinically indistinguishable from manifestations of CRS. CRS events occurred predominantly in cycle 1 and were mainly associated with Day 1 and Day 15 dose administrations.

Patients should be premedicated with corticosteroids, antipyretics and antihistamines at least through cycle 2. Patients must receive adequate hydration prior to the administration of Lunsumio. Patients should be monitored for signs or symptoms of CRS. Patients should be counselled to seek immediate medical attention should signs or symptoms of CRS occur at any time. Physicians should institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated. (see section 4.2).

Serious infections

Serious infections such as pneumonia, bacteraemia, and sepsis or septic shock have occurred in patients receiving Lunsumio, some of which were life-threatening or fatal events (see section 4.8). Febrile neutropenia was observed in patients after receiving Lunsumio infusion.
Lunsumio should not be administered in the presence of active infections. Caution should be exercised when considering the use of Lunsumio in patients with a history of recurring or chronic infections (e.g., chronic, active Epstein-Barr Virus), with underlying conditions that may predispose to infections or who have had significant prior immunosuppressive treatment. Patients should be administered prophylactic antibacterial, antiviral and/or antifungal medicinal products, as appropriate. Patients should be monitored for signs and symptoms of infection, before and after Lunsumio administration, and treated appropriately. In the event of febrile neutropenia, patients should be evaluated for infection and managed with antibiotics, fluids and other supportive care, according to local guidelines.

Tumour flare

Tumour flare has been reported in patients treated with Lunsumio (see section 4.8). Manifestations included new or worsening pleural effusions, localised pain and swelling at the sites of lymphoma lesions and tumour inflammation. Consistent with the mechanism of action of Lunsumio, tumour flare is likely due to the influx of T-cells into tumour sites following Lunsumio administration.

There are no specific risk factors for tumour flare that have been identified, however, there is a heightened risk of compromise and morbidity due to mass effect secondary to tumour flare in patients with bulky tumours located in close proximity to airways and/or a vital organ. Patients treated with Lunsumio should be monitored and evaluated for tumour flare at critical anatomical sites.

Tumour lysis syndrome (TLS)

TLS has been reported in patients receiving Lunsumio (see section 4.8). Patients must have adequate hydration prior to the administration of Lunsumio. Patients should be administered prophylactic anti-hyperuricemic therapy (e.g allopurinol, rasburicase), as appropriate. Patients should be monitored for signs or symptoms of TLS, especially patients with high tumour burden or rapidly proliferative tumours, and patients with reduced renal function. Patients should be monitored for blood chemistries and abnormalities should be managed promptly.

Immunisation

Live and/or live-attenuated vaccines should not be given concurrently with Lunsumio. Studies have not been conducted in patients who recently received live vaccines.

Patient card

The prescriber must discuss the risks of Lunsumio therapy with the patient. The patient should be provided with the patient card and instructed to carry it at all times. The patient card describes the common signs and symptoms of CRS, and provides instructions on when a patient should seek medical attention.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

A transient clinically relevant effect on CYP450 substrates with a narrow therapeutic index (e.g. warfarin, voriconazole, cyclosporine, etc) cannot be excluded, since initiation of Lunsumio treatment causes a transient increase in cytokine levels which may cause inhibition of CYP450 enzymes. On initiation of Lunsumio therapy in patients being treated with CYP450 substrates with a narrow therapeutic index, therapeutic monitoring should be considered. The dose of the concomitant medicinal product should be adjusted as needed.
4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception

Women of childbearing potential should use effective contraception while receiving Lunsumio and for at least 3 months after the last infusion of Lunsumio.

Pregnancy

There are no data from the use of Lunsumio in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Lunsumio is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is unknown whether mosunetuzumab/metabolites are excreted in human milk. A risk to newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Lunsumio therapy.

Fertility

No human data on fertility are available. No impairments were observed in male or female reproductive organs in the 26-week toxicity studies with cynomolgus monkeys at exposures (AUC) similar to exposure (AUC) in patients receiving the recommended dose.

4.7 Effects on ability to drive and use machines

Lunsumio has minor influence on the ability to drive and use machines. Patients who experience events that impair consciousness should be evaluated and advised not to drive and to refrain from operating heavy or potentially dangerous machines until events are resolved.

4.8 Undesirable effects

Summary of safety profile

The adverse reactions (ARs) described in this section were identified from the pivotal clinical trial GO29781 in patients treated at the recommended dose (n=218). Patients had follicular lymphoma (41.3%), diffuse large B-cell lymphoma/transformed follicular lymphoma (40.4%) mantle cell lymphoma (11.5%), Richter’s transformation (6.4%), and other histologies (0.5%). The median number of cycles of Lunsumio received was 8 (range 1 -17), 37% of patients received 8 cycles, and 15% received more than 8 cycles up to 17 cycles.

The most common adverse reactions (≥ 20%) observed were cytokine release syndrome, neutropenia, pyrexia, hypophosphatemia and headache. The most common serious adverse reactions (≥ 2%) observed included cytokine release syndrome (CRS) (21% by ASTCT grading system), pyrexia (5%), and pneumonia (3%). Nine of 218 patients (4.1%) discontinued Lunsumio due to an adverse event. CRS was the only adverse reaction that led to discontinuation in more than one patient (2 patients [0.9%]).

Tabulated list of adverse reactions

The adverse reactions are listed below by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
<table>
<thead>
<tr>
<th>System organ class / preferred term or adverse reaction</th>
<th>All grades</th>
<th>Grade 3 – 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumour flare</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia$^1$</td>
<td>Very common</td>
<td>Very common</td>
</tr>
<tr>
<td>Anaemia</td>
<td>Very common</td>
<td>Common</td>
</tr>
<tr>
<td>Thrombocytopenia$^2$</td>
<td>Very common</td>
<td>Common</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokine release syndrome$^3$</td>
<td>Very common</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypophosphataemia</td>
<td>Very common</td>
<td>Very common</td>
</tr>
<tr>
<td>Hypokalaemia</td>
<td>Very common</td>
<td>Common</td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>Very common</td>
<td>Very rare</td>
</tr>
<tr>
<td>Tumour lysis syndrome</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>Very common</td>
<td>Uncommon</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Very common</td>
<td>Very rare</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>Very common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Pruritus</td>
<td>Very common</td>
<td>Very rare</td>
</tr>
<tr>
<td>Dry skin</td>
<td>Very common</td>
<td>Very rare</td>
</tr>
</tbody>
</table>
## System organ class / preferred term or adverse reaction

<table>
<thead>
<tr>
<th></th>
<th>All grades</th>
<th>Grade 3 – 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyrexia</td>
<td>Very common</td>
<td>Common</td>
</tr>
<tr>
<td>Chills</td>
<td>Very common</td>
<td>Uncommon</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine aminotransferase, increased</td>
<td>Very common</td>
<td>Common</td>
</tr>
<tr>
<td>Aspartate aminotransferase, increased</td>
<td>Common</td>
<td>Common</td>
</tr>
</tbody>
</table>

1 Neutropenia includes neutropenia and neutrophil count decreased  
2 Thrombocytopenia includes thrombocytopenia and platelet count decreased  
3 By American Society for Transplant and Cellular Therapy

### Description of selected adverse reactions

**Cytokine release syndrome (CRS)**

CRS (ASTCT grading system) of any grade occurred in 39% (86/218) of patients, with grade 2 occurring in 14%, grade 3 occurring in 2.3%, and grade 4 occurring in 0.5% of patients treated with Lunsumio. The one patient with the grade 4 event was a patient with FL in the leukemic phase who also experienced concurrent TLS.

CRS of any grade occurred in 15% of patients after the Cycle 1, Day 1 dose; 5% after the Cycle 1, Day 8 dose; 33% after the Cycle 1, Day 15 dose; 5% occurred in patients after the Cycle 2 and 1% in Cycles 3 and beyond. The median time to CRS onset from the start of administration in Cycle 1 Day 1 was 5 hours (range: 1-73 hours), Cycle 1 Day 8 was 28 hours (range: 5-81 hours), Cycle 1 Day 15 was 25 hours (range: 0.1-391 hours), and Cycle 2 Day 1 was 46 hours (range: 12-82 hours). CRS resolved in all patients, and the median duration of CRS events was 3 days (range 1-29 days).

Of the 86 patients that experienced CRS, the most common signs and symptoms of CRS included pyrexia (98%), chills (36%), hypotension (35%), tachycardia (24%), hypoxia (22%) and headache (16%).

Tocilizumab and/or corticosteroids were used to manage a CRS event in 16% of patients: 6% received tocilizumab alone, 6% received corticosteroids alone, and 4% received both tocilizumab and corticosteroids. Among the 10% of patients who received tocilizumab (with or without a corticosteroid), 86% received only one dose of tocilizumab, with no more than two doses of tocilizumab administered for a single CRS event. In patients experiencing Grade 2 CRS, 48% of patients were treated with symptomatic management without corticosteroids or tocilizumab, 18% received tocilizumab alone, 21% received corticosteroids alone, and 12% received both corticosteroids and tocilizumab. Patients with grade 3 or grade 4 CRS received tocilizumab, corticosteroids, vasopressors and/or oxygen supplementation. Three percent of patients experienced hypotension and/or hypoxia without fever following Lunsumio administration; 2% of patients received tocilizumab and/or corticosteroids in the absence of fever.

Hospitalizations due to CRS occurred in 21% of patients and the median duration of hospitalization was 5 days (range 0-30 days).
Neutropenia

Neutropenia of any grade occurred in 28% of patients, including 24% Grade 3-4 events. The median time to onset of first neutropenia/neutrophil count decreased events was 48 days (range: 1-280 days), with median duration of 8 days (range: 1-314 days). Of the 60 patients who had neutropenia/neutrophil count decreased events 68% received treatment G-CSF to treat the events.

Serious infections

Serious infections of any grade occurred in 17% of patients. 1.8% of patients experienced serious infections concurrently with grade 3-4 neutropenia. The median time to onset of first serious infection was 50 days (range: 1-561 days), with median duration of 12 days (range: 2-174 days). Grade 5 events occurred in 0.9% of patients, which included pneumonia and sepsis.

Tumour flare

Tumour flare (including pleural effusion and tumour inflammation) occurred in 4% of patients, which included 1.8% grade 2 and 2.3% grade 3 events. The median time to onset was 13 days (range 5-84 days), and median duration was 10 days (range 1-77 days).

Tumour Lysis Syndrome (TLS)

TLS occurred in 0.9% of patients, concurrent with CRS. One patient with follicular lymphoma was in the leukemic phase who experienced Grade 4 TLS. TLS onset was on days 2 and 24, and resolved within 4 and 6 days, respectively.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents; other antineoplastic agents; monoclonal antibodies, ATC code: L01XC

Mechanism of action

Mosunetuzumab is an anti-CD20/CD3 T-cell engaging bispecific antibody targeting CD20-expressing B-cells. It is a conditional agonist; targeted B-cell killing is observed only upon simultaneous binding to CD20 on B-cells and CD3 on T-cells. Engagement of both arms of mosunetuzumab results in the formation of an immunologic synapse between a target B cell and a cytotoxic T cell leading to T-cell activation. Subsequent directed release of perforin and granzymes from T-cell activation through the immunologic synapsis induce B-cell lysis leading to cell death.

Lunsumio caused B-cell depletion (defined as CD19 B-cell counts < 0.07 x 10^9/L) and hypogammaglobulinemia (defined as IgG levels < 500 mg/dL).
Clinical efficacy and safety

Relapsed or refractory B-cell Non-Hodgkin's lymphoma

An open-label, multicentre, multi-cohort study (GO29781) was conducted to evaluate Lunsumio in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma for whom there was no available therapy expected to improve survival. In the follicular lymphoma (FL) cohort (n=90), patients with relapsed or refractory FL (Grade 1-3A) were required to have received at least two prior systemic therapies, including an anti-CD20 monoclonal antibody and an alkylating agent. Patients with FL Grade 3b and patients with transformed FL at study entry were not eligible; those with a history of transformed FL but FL Grade 1-3A at study entry were included in the FL cohort.

The study excluded patients with Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2, significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina), significant active pulmonary disease, impaired renal functions (Creatinine clearance [CrCl] < 60 mL/min with elevated serum creatinine level), active autoimmune disease requiring immunosuppressive therapy, active infections (i.e., chronic active EBV, acute or chronic hepatitis C, hepatitis B, HIV), progressive multifocal leukoencephalopathy, current or a history of CNS lymphoma or CNS disease, a history of macrophage activation syndrome / hemophagocytic lymphohistiocytosis, prior allogeneic stem cell transplant, or prior organ transplantation.

Patients received Lunsumio intravenously in a 21-day Cycle as follows:

- Cycle 1 Day 1: 1 mg
- Cycle 1 Day 8: 2 mg
- Cycle 1 Day 15: 60 mg
- Cycle 2 Day 1: 60 mg
- Cycle 3 and beyond Day 1: 30 mg

The median number of cycles was 8, 59% received 8 cycles, and 18% received more than 8 cycles up to 17 cycles.

The median age was 60 years (range 29 to 90 years) with 31% being > age 65, and 7.8% being ≥ age 75. Sixty-one percent were male, 82% were white, 9% were Asian, 4% were Black, 100% had an ECOG performance status of 0 or 1 and 34% of patients had bulky disease (at least one lesion > 6 cm). The median number of prior therapies was 3 (range: 2-10), with 38% receiving 2 prior therapies, 31% receiving 3 prior therapies and 31% receiving more than 3 prior therapies.

All patients received prior anti-CD20 and alkylator therapies, 21% received autologous stem cell transplant, 19% received PI3K inhibitors, 9% received prior rituximab plus lenalidomide therapy, and 3% received CAR-T therapies. Seventy-nine percent of patients were refractory to prior anti-CD20 monoclonal antibody therapy and 53% were refractory to both anti-CD20 monoclonal antibody and alkylator therapy. Sixty-nine percent of patients were refractory to the last prior therapy and 52% had progression of disease within 24 months of first systemic therapy.

The primary efficacy endpoint was complete response (CR) as assessed by an independent review facility (IRF) according to standard criteria for NHL (Cheson 2007). The efficacy results are summarised in Table 5.
Table 5  Summary of efficacy in patients with relapsed/refractory FL

<table>
<thead>
<tr>
<th>Efficacy parameter</th>
<th>Lunsumio N=90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median observation time 18.3 months (range 2 – 27 months)</td>
<td></td>
</tr>
<tr>
<td><strong>Complete Response (CR), n (%), (95% CI)</strong></td>
<td>54 (60.0) (49.1, 70.2)</td>
</tr>
<tr>
<td><strong>Objective Response Rate (ORR), n (%), (95% CI)</strong></td>
<td>72 (80.0) (70.3, 87.7)</td>
</tr>
<tr>
<td>Partial Response (PR) n (%), (95% CI)</td>
<td>18 (20.0) (12.3, 29.8)</td>
</tr>
<tr>
<td><strong>Duration of Response (DOR)¹</strong></td>
<td></td>
</tr>
<tr>
<td>Patients with event, n (%)</td>
<td>29 (40.3)</td>
</tr>
<tr>
<td>Median, months (95% CI)</td>
<td>22.8 (9.7, NR)</td>
</tr>
<tr>
<td>K-M event-free proportion</td>
<td></td>
</tr>
<tr>
<td>12 months (95% CI)</td>
<td>61.8 (50.0, 73.7)</td>
</tr>
<tr>
<td>18 months (95% CI)</td>
<td>56.9 (44.1, 69.6)</td>
</tr>
<tr>
<td><strong>Duration of Complete Response (DOCR)²</strong></td>
<td></td>
</tr>
<tr>
<td>Patients with event, n (%)</td>
<td>16 (29.6)</td>
</tr>
<tr>
<td>Median, months (95% CI)</td>
<td>NR (14.6, NR)</td>
</tr>
<tr>
<td>K-M event-free proportion,</td>
<td></td>
</tr>
<tr>
<td>12 months (95% CI)</td>
<td>71.4 (57.9, 84.9)</td>
</tr>
<tr>
<td>18 months (95% CI)</td>
<td>63.7 (48.0, 79.4)</td>
</tr>
</tbody>
</table>

CI=confidence interval; K-M=Kaplan-Meier; NR=not reached.

Clinical Cut-off: 27 August 2021

Hypothesis testing was conducted on the primary endpoint of IRF assessed CR rate.

¹ DOR is defined as the time from the initial occurrence of a documented PR or CR until the patient experiences an event (documented disease progression or death due to any cause, whichever occurs first).

² DOCR is defined as the time from the initial occurrence of a documented CR until the patient experiences an event (documented disease progression or death due to any cause, whichever occurs first).

The median follow-up for DOR was 14.9 months. Additional exploratory efficacy outcomes included the median time to first response (1.4 months, range: 1.1 - 8.9) and the median time to first complete response (3.0 months, range: 1.1- 18.9).

Immunogenicity

The immunogenicity of mosunetuzumab was evaluated using an enzyme-linked immunosorbent assay (ELISA). No patients tested positive for anti-mosunetuzumab antibodies in 418 ADA-evaluable patients who received Lunsumio single-agent intravenous treatments in Study GO27981. Based on the available information, the clinical relevance of anti-mosunetuzumab antibodies could not be assessed.
Paediatric population

The European Medicines Agency has waived the obligation to submit results of studies with Lunsumio in all subsets of the paediatric population for the treatment of mature B-cell neoplasms (see section 4.2 for information on paediatric use).

Conditional approval

This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.

5.2 Pharmacokinetic properties

Mosunetuzumab pharmacokinetic (PK) exposure increased in an approximately dose-proportional manner over the dose range studied, from 0.05 to 60 mg. The population pharmacokinetic following intravenous administrations of Lunsumio was described by a 2-compartment PK model with time-dependent clearance, which was parameterized as descending to a steady-state plateau (CLss) from a baseline value (CLbase) at the start of treatment according to transitional half-life of 16.3 days. Moderate to high pharmacokinetic variability for mosunetuzumab was observed and characterized by inter-individual variability (IIV) ranging from 18% to 86% coefficient of variation (CV) for mosunetuzumab PK parameters: IIV was estimated for CLbase (63% CV), central volume of distribution (31% CV), peripheral volume of distribution (25% CV), CLss (18% CV), and transitional half-life (86% CV).

After the first two Cycles (i.e., 42 days) of the dosing with Lunsumio, the serum concentration reaches the Cmax at the end of dose of Cycle 2 Day 1 of the Lunsumio intravenous infusion with an average maximal concentration of 17.9 µg/mL and %CV of 49.6%. The average total two cycles (42 days) mosunetuzumab exposure AUC was 126 day•µg/mL with %CV of 44.4%.

Absorption

Lunsumio is administered intravenously.

Distribution

The population estimate of central volume of distribution for mosunetuzumab was 5.49 L with intravenous infusion of Lunsumio. Because mosunetuzumab is an antibody, protein binding studies were not conducted.

Biotransformation

The metabolic pathway of mosunetuzumab has not been directly studied. Like other protein therapeutics, mosunetuzumab is expected to be degraded into small peptides and amino acids via catabolic pathways.

Elimination

Based on a population pharmacokinetic analysis, the estimated mean CLss and baseline clearance (CLbase) were 1.08 L/day and 0.584 L/day, respectively. The terminal half-life estimate was 16.1 days at steady state based on population pharmacokinetic model estimates. The results obtained in study GO29781 indicate that mosunetuzumab serum concentration reaches the Cmax at the end of the intravenous infusion and declines in a bi-exponential fashion.
Special populations

Elderly

Age did not have an effect on the pharmacokinetics of mosunetuzumab based on a population pharmacokinetic analysis with patients aged 19-96 years (n=439). No clinically important difference was observed in the pharmacokinetics of mosunetuzumab for patients in this age group.

Bodyweight

Like other therapeutic proteins, bodyweight was positively associated with mosunetuzumab estimated clearance and volume of distribution. However, based on exposure-response analysis and clinical exposure margins, considering the exposures in patients at either “low” (<50 kg) or “high” (≥112 kg) weight, no dose adjustment is required due to patient bodyweight.

Gender

Based upon population pharmacokinetic analysis, steady-state clearance of mosunetuzumab is marginally lower in females (~13%) compared to males. No dose adjustment is required due to gender, based on exposure-response analysis.

Race

Race (Asian vs. non-Asian) was not identified as a covariate influencing mosunetuzumab pharmacokinetics.

Renal impairment

No dedicated studies have been conducted to determine the effect of renal impairment on the pharmacokinetics of mosunetuzumab. The renal elimination of intact mosunetuzumab, an IgG monoclonal antibody, is expected to be low and of minor importance.

The population PK analysis of mosunetuzumab showed that creatinine clearance (CrCl) does not affect pharmacokinetics of mosunetuzumab. Pharmacokinetics of mosunetuzumab in patients with mild (CrCl 60 to 89 mL/min, n=178) or moderate (CrCl 30 to 59 mL/min, n=53) renal impairment were similar to those in patients with normal renal function (CrCl ≥ 90 mL/min, n=200). Pharmacokinetic data in patients with severe renal impairment (CrCl 15 to 29 mL/min) is limited (n=1), therefore no dose recommendations can be made. Lunsumio was not studied in patients with end-stage renal disease and/or who are on dialysis.

Hepatic impairment

No specific studies have been conducted to determine the effect of hepatic impairment on the pharmacokinetics of mosunetuzumab. IgGs are mainly eliminated via intracellular catabolism and hepatic impairment is not expected to influence clearance of mosunetuzumab.

The population PK analysis of mosunetuzumab showed that hepatic impairment does not affect pharmacokinetics of mosunetuzumab. Pharmacokinetics of mosunetuzumab in patients with mild hepatic impairment (total bilirubin > ULN to 1.5 x ULN or AST > ULN, n=53) were similar to those in patients with normal hepatic function (n=384). The number of patients with moderate hepatic impairment is limited (total bilirubin > 1.5–3 x ULN, any AST, n=2) and no patients with severe hepatic impairment have been studied.

Paediatric population

No studies have been conducted to investigate the pharmacokinetics of mosunetuzumab in the paediatric population (<18 years old).
5.3 Preclinical safety data

Systemic toxicity

Key nonclinical findings with mosunetuzumab identified in single- and repeat-dose toxicity studies up to 26-weeks in duration included transient post-dose CRS primarily limited to the first dose, vascular/perivascular inflammatory cell infiltrates that were primarily in the CNS and infrequently in other organs that were likely secondary to cytokine release and immune cell activation, and increased susceptibility to infection following chronic dosing due to sustained B-cell depletion.

All of the findings were considered pharmacologically-mediated effects and reversible. Across studies there was a single incidence of convulsion in one animal at C\text{max} and AUC exposures (time-averaged over 7 days) of 3.3- and 1.8- fold higher, respectively, than those in patients receiving Lunsumio at the recommended dose and schedule in Study GO29781.

Impairment of fertility

An assessment of the male and female reproductive organs was included in a 26-week chronic toxicity study in sexually mature cynomolgus monkeys administered by intravenous infusion. Mosunetuzumab had no effect on either male or female reproductive organs at exposures (AUC) similar to exposure (AUC) in patients receiving the recommended dose.

Reproductive toxicity

No developmental toxicity studies in animals have been conducted with mosunetuzumab. Based on low placental transfer of antibodies during the first trimester, the mechanism of action and available data of mosunetuzumab, and the data on the anti-CD20 antibody class, the risk for teratogenicity is low. Studies with mosunetuzumab in non-pregnant animals have demonstrated that prolonged B-cell depletion can lead to increased risk of opportunistic infection, which may cause foetal loss. Transient CRS associated with Lunsumio administration may also be harmful to pregnancy.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

L-histidine
L-methionine
Acetic acid (pH adjustment)
Sucrose
Polysorbate 20 (E 432)
Water for injections

6.2 Incompatibilities

- Do not mix Lunsumio with, or administer through the same infusion line, as other medicinal products.
- Do not use solvents other than sodium chloride 9 mg/mL (0.9%) solution for injection or sodium chloride 4.5 mg/mL (0.45%) solution for injection to dilute Lunsumio since its use has not been tested.
- No incompatibilities have been observed between Lunsumio and intravenous infusion bags with product contacting materials of polyvinyl chloride (PVC), or polyolefins (PO) such as polyethylene (PE) and polypropylene (PP). In addition, no incompatibilities have been observed with infusion sets or infusion aids with product contacting materials of PVC, PE, polycarbonate (PC), polyetherurethane (PEU), fluorinated ethylene propylene (FEP), or polytetrafluoroethylene.
(PTFE), or with drip chamber filter membrane composed of polyamide (PA).

- Do not use an in-line filter.

### 6.3 Shelf life

#### Unopened vial

2 years

#### Diluted solution

Chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C - 8 °C and 24 hours at 9 °C - 30 °C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

### 6.4 Special precautions for storage

Store in a refrigerator (2 °C - 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

### 6.5 Nature and contents of container

#### 1 mg concentrate for solution for infusion

Type I glass-vial with a butyl rubber stopper and an aluminium seal with a plastic dark grey flip-off cap containing 1 mg of concentrate for solution for infusion.

Pack of one vial.

#### 30 mg concentrate for solution for infusion

Type I glass-vial with a butyl rubber stopper and an aluminium seal with a plastic light blue flip-off cap containing 30 mg of concentrate for solution for infusion.

Pack of one vial.

### 6.6 Special precautions for disposal and other handling

#### General precautions

Lunsumio contains no preservative and is intended for single-dose only. Proper aseptic technique throughout the handling of this medicinal product should be followed. Do not shake.

#### Instructions for dilution

Lunsumio must be diluted into a PVC or polyolefin (PO) such as polyethylene (PE) and polypropylene infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection or sodium chloride 4.5 mg/mL (0.45%) solution for injection by a healthcare professional using aseptic technique prior to administration.

Use sterile needle and syringe to prepare Lunsumio. Discard any unused portion.
A dedicated infusion line should be used during intravenous administration.

**Do not use an in-line filter to administer Lunsumio.**

Drip chamber filters can be used to administer Lunsumio.

**Preparation for infusion**

1. Withdraw and discard a volume of sodium chloride 9 mg/mL (0.9%) solution for injection or sodium chloride 4.5 mg/mL (0.45%) solution for injection equal to the volume of the Lunsumio required for the patient’s dose from the infusion bag according to the Table 6 below.
2. Withdraw the required volume of Lunsumio from the vial using a sterile syringe and dilute into the infusion bag. Discard any unused portion left in the vial.

**Table 6: Dilution of Lunsumio**

<table>
<thead>
<tr>
<th>Day of treatment</th>
<th>Dose of Lunsumio</th>
<th>Volume of Lunsumio in sodium chloride 9 mg/mL (0.9%) or 4.5 mg/mL (0.45%) solution for injection</th>
<th>Size of infusion bag</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1</td>
<td>Day 1</td>
<td>1 mg</td>
<td>1 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 mL</td>
<td>50 mL or 100 mL</td>
</tr>
<tr>
<td></td>
<td>Day 8</td>
<td>2 mg</td>
<td>2 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 mL</td>
<td>50 mL or 100 mL</td>
</tr>
<tr>
<td></td>
<td>Day 1 or 5</td>
<td>60 mg</td>
<td>60 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60 mL</td>
<td>100 mL or 250 mL</td>
</tr>
<tr>
<td>Cycle 2</td>
<td>Day 1</td>
<td>60 mg</td>
<td>60 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60 mL</td>
<td>100 mL or 250 mL</td>
</tr>
<tr>
<td>Cycle 3 and beyond</td>
<td>Day 1</td>
<td>30 mg</td>
<td>30 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 mL</td>
<td>100 mL or 250 mL</td>
</tr>
</tbody>
</table>

3. Gently mix the infusion bag by slowly inverting the bag. Do not shake.
4. Inspect the infusion bag for particulates and discard if present.
5. Apply the peel-off label from the leaflet to the infusion bag.

For storage conditions of the infusion bags, see section 6.3.

**Disposal**

The release of pharmaceuticals into the environment should be minimised. Medicinal products should not be disposed of via wastewater and disposal through household waste should be avoided. The following points should be strictly adhered to regarding the use and disposal of syringes and other medicinal sharps:

- Needles and syringes should never be reused.
- Place all used needles and syringes into a sharps container (puncture-proof disposable container).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1649/001
EU/1/22/1649/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 3 June 2022

10. DATE OF REVISION OF THE TEXT

ANNEX II

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

E. SPECIFIC OBLIGATION TO COMPLETE POSTAUTHORIZATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORIZATION
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
USA

Name and address of the manufacturer responsible for batch release

Roche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
GERMANY

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in Article 9 of Regulation (EC) No 507/2006 and, accordingly, the marketing authorisation holder (MAH) shall submit PSURs every 6 months.

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c (7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• Additional risk minimisation measures

The MAH shall ensure that in each Member State where Lunsumio is marketed, all patients/carers who are expected to use Lunsumio have access to/are provided with the Patient Card which will inform and explain to patients the risks of cytokine release syndrome (CRS). The Patient Card also includes a warning message for healthcare professionals treating the patient that the patient is receiving Lunsumio.

The patient card shall contain the following key messages:
• A description of the key signs and symptoms of CRS
• A description of when to seek urgent attention from the healthcare provider or seek emergency help, should signs and symptoms of CRS present themselves
• The prescribing physician’s contact details

E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION

This being a conditional marketing authorisation and pursuant to Article 14-a(4) of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:

<table>
<thead>
<tr>
<th>Description</th>
<th>Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>In order to provide further evidence of efficacy and safety of mosunetuzumab in follicular lymphoma, the MAH will provide results from Study GO42909, a randomised, open-label, multicentre trial evaluating mosunetuzumab in combination with lenalidomide in comparison to rituximab in combination with lenalidomide in patients with follicular lymphoma after at least one line of systemic therapy.</td>
<td>Q1 2026</td>
</tr>
</tbody>
</table>
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Lunsumio 1 mg concentrate for solution for infusion
mosunetuzumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 1 mg mosunetuzumab at a concentration of 1 mg/ml.

3. LIST OF EXCIPIENTS

Excipients: L-histidine, L-methionine, acetic acid, sucrose, polysorbate 20, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion
1 mg/1 mL
1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only
Read the package leaflet before use
For intravenous use after dilution

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not shake the vial
Do not use in-line filter

On the inside flap of the outer carton

⚠️
Do not use in-line filter
Apply peel-off label from the enclosed leaflet to the infusion bag
8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

   Store in a refrigerator
   Do not freeze
   Keep the vial in the outer carton in order to protect from light

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

    Roche Registration GmbH
    Emil-Barell-Strasse 1
    79639 Grenzach-Wyhlen
    Germany

12. **MARKETING AUTHORISATION NUMBER(S)**

    EU/1/22/1649/001

13. **BATCH NUMBER**

    Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

    Justification for not including Braille accepted

17. **UNIQUE IDENTIFIER – 2D BARCODE**

    2D barcode carrying unique identifier included
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

<table>
<thead>
<tr>
<th>PC</th>
<th>SN</th>
<th>NN</th>
</tr>
</thead>
</table>


MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
2 mL VIAL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Lunsumio 1 mg sterile concentrate
mosunetuzumab
IV use after dilution

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mg/1 mL

6. OTHER
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Lunsumio 30 mg concentrate for solution for infusion
mosunetuzumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 30 mg mosunetuzumab at a concentration of 1 mg/ml.

3. LIST OF EXCIPIENTS

Excipients: L-histidine, L-methionine, acetic acid, sucrose, polysorbate 20, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion
30 mg/30 mL
1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only
Read the package leaflet before use
For intravenous use after dilution

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not shake the vial
Do not use in-line filter

On the inside flap of the outer carton

⚠️
Do not use in-line filter
Apply peel-off label from the enclosed leaflet to the infusion bag
<table>
<thead>
<tr>
<th>8.</th>
<th>EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9.</th>
<th>SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Store in a refrigerator</td>
</tr>
<tr>
<td></td>
<td>Do not freeze</td>
</tr>
<tr>
<td></td>
<td>Keep the vial in the outer carton in order to protect from light</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10.</th>
<th>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>11.</th>
<th>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Roche Registration GmbH</td>
</tr>
<tr>
<td></td>
<td>Emil-Barell-Strasse 1</td>
</tr>
<tr>
<td></td>
<td>79639 Grenzach-Wyhlen</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12.</th>
<th>MARKETING AUTHORISATION NUMBER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EU/1/22/1649/002</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13.</th>
<th>BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Batch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14.</th>
<th>GENERAL CLASSIFICATION FOR SUPPLY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>15.</th>
<th>INSTRUCTIONS ON USE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>16.</th>
<th>INFORMATION IN BRAILLE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Justification for not including Braille accepted</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17.</th>
<th>UNIQUE IDENTIFIER – 2D BARCODE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2D barcode carrying unique identifier included</td>
</tr>
</tbody>
</table>
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
### MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

**50 mL VIAL**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lunsumio 30 mg concentrate for solution for infusion</td>
</tr>
<tr>
<td>mosunetuzumab</td>
</tr>
<tr>
<td>For intravenous use after dilution</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. METHOD OF ADMINISTRATION</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 mg/30 mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. OTHER</th>
</tr>
</thead>
</table>
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Lunsumio is and what it is used for
2. What you need to know before you use Lunsumio
3. How to take Lunsumio
4. Possible side effects
5. How to store Lunsumio
6. Contents of the pack and other information

1. What Lunsumio is and what it is used for

Lunsumio contains the active substance mosunetuzumab, which is a type of antibody. This is a cancer medicine. It is used to treat adults who have a blood cancer called follicular lymphoma (FL).

In FL, a type of white blood cells called ‘B cells’ become cancerous. The abnormal B cells do not work properly and grow too quickly, crowding out the normal B cells in the bone marrow and lymph nodes that help protect you from infection.

Lunsumio is given to patients who have tried at least two previous treatments for FL, when either the cancer has not responded to them, or it has come back again.

How Lunsumio works

The active substance in Lunsumio, mosunetuzumab, is a monoclonal antibody, a type of protein that attaches to specific targets in the body. In this case, mosunetuzumab attaches to a target substance found on B cells, including the cancerous B cells, and another target found on ‘T cells’, a different type of white blood cell. T cells are another part of the body’s defences that can destroy invading cells. By attaching the two cells together like a bridge, Lunsumio encourages the T cells to destroy the cancerous B cells. This helps control the FL and prevent its spread.

2. What you need to know before you use Lunsumio

You must not be given Lunsumio

- if you are allergic to mosunetuzumab or any of the other ingredients of this medicine (listed in section 6).
If you are not sure, talk to your doctor or nurse before you are given Lunsumio.

**Warnings and precautions**

Talk to your doctor or nurse before you are given Lunsumio if any of the following apply to you (or you are not sure):

- you have ever had heart, lung or kidney problems
- you have an infection, or have had an infection in the past which lasted a long time or keeps coming back
- you are due to have a vaccine or you know you may need to have one in the near future.

If any of the above apply to you (or you are not sure), talk to your doctor or nurse before having this medicine.

Tell your doctor straight away if you get symptoms of any of the side effects listed below during or after treatment with Lunsumio. You may need additional medical treatment. The symptoms of each side effect are listed in section 4.

- **Cytokine release syndrome** – a condition associated with medicines that stimulate T cells.
  - Before each infusion, you may be given medicines, which help reduce possible side effects of cytokine release syndrome.
- **Tumour lysis syndrome** – some people may get unusual levels of some salts in the blood – caused by the fast breakdown of cancer cells during treatment.
  - Your doctor or nurse will do blood tests to check for this condition. Before each infusion, you should be well-hydrated and may be given medicines that can help reduce high levels of uric acid. These may help reduce possible side effects of tumour lysis syndrome.
- **Tumour flare** – as your cancer is destroyed, it may react and appear to get worse – this is called ‘tumour flare reaction’.
- **Infections** – you may get signs of infection, which can vary depending on where in the body the infection is.

**Children and adolescents**

This medicine should not be used in children or adolescents under the age of 18. This is because there is no information about use in this age group.

**Other medicines and Lunsumio**

Tell your doctor if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines.

**Pregnancy and breast-feeding**

It is important to tell your doctor before and during treatment if you are pregnant, think you may be pregnant, or are planning to get pregnant. This is because Lunsumio may affect your unborn baby.

- Do not use Lunsumio during pregnancy, unless after discussion with your doctor, it is agreed that the benefits of treatment outweigh any risk to the unborn baby.

**Contraception**

Women who could become pregnant must use effective contraception during treatment – and for 3 months after the last dose of Lunsumio.

- Talk to your doctor or nurse about suitable methods of contraception.
Breast-feeding

You must not breast-feed during and for at least 3 months after your last treatment. This is because it is not known whether any Lunsumio passes into breast milk and could therefore affect the baby.

Driving and using machines

Lunsumio has minor influence on your ability to drive, cycle or use any tools or machines. If you feel any symptoms that may affect your ability to drive, do not drive, cycle or use tools or machines until the reaction stops. See section 4 for more information about side effects.

3. How Lunsumio is given

Lunsumio is given under the supervision of a doctor experienced in giving such treatments. Follow the treatment schedule explained to you by your doctor. Check with your doctor if you are not sure.

How Lunsumio is given

It is given into a vein, as a drip (infusion).
- It is given over 4 hours during the first cycle. Each cycle is 21 days and in the first cycle, you will be given the 4 hour infusion on day 1, day 8 and day 15.
- If side effects are not too severe, the dose may be given over 2 hours during the following cycles.

Medicines given before Lunsumio treatment

You may be given other medicines 30 to 60 minutes before you are given Lunsumio. This is to help prevent infusion reactions and fever. These other medicines may include:
- Corticosteroids – such as dexamethasone or methylprednisolone
- Paracetamol
- An antihistamine - such as diphenhydramine

How much Lunsumio is given

Lunsumio is normally given in cycles of 21 days. The recommended treatment duration is at least 8 treatment cycles. However, depending on side effects and how the disease responds to treatment, you may be given up to 17 cycles.

In cycle 1, you will be given 3 doses of Lunsumio in the 21 days:
- Day 1: 1 mg
- Day 8: 2 mg
- Day 15: 60 mg

In cycle 2, you will be given just one dose:
- Day 1: 60 mg

In cycles 3 to 17, you will be given just one dose:
- Day 1: 30 mg

If you miss a dose of Lunsumio

If you miss an appointment, make another one straight away. For the treatment to be fully effective, it is very important not to miss a dose.
If you stop receiving Lunsumio

Do not stop treatment with Lunsumio unless you have discussed this with your doctor. This is because stopping treatment may make your condition worse.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Tell your doctor straight away if you notice any of the symptoms of the following serious side effects. You may only get one or some of these symptoms.

**Cytokine release syndrome**
Symptoms can include:
- fever (38°C or higher)
- chills or shaking chills
- cold or pale clammy skin
- difficulty breathing
- feeling dizzy or lightheaded
- fast or uneven heartbeat
- confusion
- feeling very tired or weak
- fainting
- blurred vision
- headache.

**Tumour lysis syndrome**
Symptoms can include:
- fever
- chills
- feeling or being sick (nausea and vomiting)
- confusion
- being short of breath
- fits (seizures)
- uneven heartbeat
- dark or cloudy urine
- unusual tiredness
- muscle or joint pain.

Shown in blood tests
- increase in potassium, phosphate or uric acid – which can cause kidney problems (part of tumour lysis syndrome)

**Tumour flare**
Symptoms can include:
- tender swollen lymph nodes
- chest pain
- cough or difficulty breathing easily
- pain at the site of the tumour.
Infections
Symptoms can include:
- fever
- cough
- chest pain
- tiredness
- shortness of breath
- painful rash
- sore throat
- burning pain when passing urine
- feeling weak or generally unwell.

If you have any of these symptoms after treatment with Lunsumio, tell your doctor straight away. You may need medical treatment.

Other side effects
Very common: may affect more than 1 in 10 people
- Rash
- Itchy skin
- Dry skin
- Diarrhoea
- Headache
- Fever
- Chills
- Cytokine release syndrome

Shown in blood tests
- Low levels of some white blood cells (neutropenia)
- Low number of red blood cells, which can cause tiredness and shortness of breath
- Low platelet count, which may make you more likely to bruise or bleed (thrombocytopenia)
- Low level of phosphate, potassium or magnesium
- High level of alanine aminotransferase in the blood

Common: may affect up to 1 in 10 people
- Lung infection
- Infection of upper airways (infection of nose, throat, sinuses)
- Urinary tract infection
- Fever due to low levels of neutrophils (a type of white blood cell)
- Tumour flare

Shown in blood tests
- Increased levels of liver enzymes, which may be a sign of liver problems

Uncommon: may affect up to 1 in 100 people
- A rapid breakdown of tumour cells resulting in chemical changes in the blood and damage to organs, including the kidneys, heart, and liver (tumour lysis syndrome)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. **How to store Lunsumio**

Lunsumio will be stored by the healthcare professionals at the hospital or clinic. The storage details that they must take account of are as follows

- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.
- Store in a refrigerator (2°C – 8°C).
- Do not freeze.
- The diluted solution should not be kept more than 24 hours at 2°C – 8°C and 24 hours at ambient temperature (9°C – 30°C).
- Keep the container in the outer carton in order to protect from light.

Your healthcare professional will dispose of any unneeded medicine appropriately. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Lunsumio contains**

- The active substance is mosunetuzumab.
- Lunsumio 1 mg: Each vial contains 1 milligram (mg) mosunetuzumab in 1 mL at a concentration of 1 mg/mL.
- Lunsumio 30 mg: Each vial contains 30 milligrams (mg) mosunetuzumab in 30 mL at a concentration of 1 mg/mL.
- The other ingredients are: L-histidine, L-methionine, acetic acid, sucrose, polysorbate 20 (E432), water for injections.

**What Lunsumio looks like and contents of the pack**

Lunsumio is a concentrate for solution for infusion (sterile concentrate). It is a clear, colourless liquid provided in a glass vial.

Each pack of Lunsumio contains one vial.

**Marketing Authorisation Holder**

Roche Registration GmbH  
Emil-Barell-Strasse 1  
79639 Grenzach-Wyhlen  
Germany

**Manufacturer**

Roche Pharma AG  
Emil-Barell-Strasse 1  
79639 Grenzach-Wyhlen  
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Address</th>
<th>Telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>België/Belgique/Belgien</td>
<td>N.V. Roche S.A.</td>
<td>+32 (0) 2 525 82 11</td>
</tr>
<tr>
<td>Lietuva</td>
<td>UAB “Roche Lietuva”</td>
<td>+370 5 2546799</td>
</tr>
<tr>
<td>България</td>
<td>Рош България ЕООД</td>
<td>+359 2 818 44 44</td>
</tr>
<tr>
<td>Luxembour/Luxemburg</td>
<td>(Voir/siehe Belgique/Belgien)</td>
<td></td>
</tr>
<tr>
<td>Česká republika</td>
<td>Roche s. r. O.</td>
<td>+420 - 2 20382111</td>
</tr>
<tr>
<td>Magyarország</td>
<td>Roche (Magyarország) Kft.</td>
<td>+36 1 279 4500</td>
</tr>
<tr>
<td>Danmark</td>
<td>Roche Pharmaceuticals A/S</td>
<td>+45 - 36 39 99 99</td>
</tr>
<tr>
<td>Malta</td>
<td>Irreferi għall-Irlanda</td>
<td></td>
</tr>
<tr>
<td>Deutschland</td>
<td>Roche Pharma AG</td>
<td>+49 (0) 7624 140</td>
</tr>
<tr>
<td>Nederland</td>
<td>Roche Nederland B.V.</td>
<td>+31 (0) 348 438050</td>
</tr>
<tr>
<td>Eesti</td>
<td>Roche Eesti OÜ</td>
<td>+372 - 6 177 380</td>
</tr>
<tr>
<td>Norge</td>
<td>Roche Norge AS</td>
<td>+47 - 22 78 90 00</td>
</tr>
<tr>
<td>Elláda</td>
<td>Roche (Hellas) A.E.</td>
<td>+30 210 61 66 100</td>
</tr>
<tr>
<td>Österreich</td>
<td>Roche Austria GmbH</td>
<td>+43 (0) 1 27739</td>
</tr>
<tr>
<td>España</td>
<td>Roche Farma S.A.</td>
<td>+34 - 91 324 81 00</td>
</tr>
<tr>
<td>Polska</td>
<td>Roche Polska Sp.z o.o.</td>
<td>+48 - 22 345 18 88</td>
</tr>
<tr>
<td>France</td>
<td>Roche</td>
<td>+33 (0) 1 47 61 40 00</td>
</tr>
<tr>
<td>Portugal</td>
<td>Roche Farmacêutica Química, Lda</td>
<td>+351 - 21 425 70 00</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Roche d.o.o.</td>
<td>+385 1 4722 333</td>
</tr>
<tr>
<td>Românía</td>
<td>Roche România S.R.L.</td>
<td>+40 21 206 47 01</td>
</tr>
</tbody>
</table>
Ireland
Roche Products (Ireland) Ltd.
Tel: +353 (0) 1 469 0700

Slovenija
Roche farmacevtska družba d.o.o.
Tel: +386 - 1 360 26 00

Ísland
Roche Pharmaceuticals A/S
c/o Icepharma hf
Simi: +354 540 8000

Slovenská republika
Roche Slovensko, s.r.o.
Tel: +421 - 2 52638201

Italia
Roche S.p.A.
Tel: +39 - 039 2471

Suomi/Finland
Roche Oy
Puh/Tel: +358 (0) 10 554 500

Κύπρος
Γ.Α.Σταμάτης & Σια Λτδ.
Τηλ: +357 - 22 76 62 76

Sverige
Roche AB
Tel: +46 (0) 8 726 1200

Latvija
Roche Latvija SIA
Tel: +371 - 6 7039831

United Kingdom (Northern Ireland)
Roche Products (Ireland) Ltd.
Tel: +44 (0) 1707 366000

This leaflet was last revised in
This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.

The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu/
The following information is intended for healthcare professionals only:

Procedures for proper handling and disposal of anticancer medicinal products should be considered.

**Instructions for dilution**

1. Withdraw and discard a volume of sodium chloride 9 mg/mL (0.9%) solution for injection or sodium chloride 4.5 mg/mL (0.45%) solution for injection equal to the volume of the Lunsumio required for the patient’s dose from the infusion bag according to the Table 6 below.
2. Withdraw the required volume of Lunsumio from the vial using a sterile syringe and dilute into the infusion bag. Discard any unused portion left in the vial.

**Table 6: Dilution of Lunsumio**

<table>
<thead>
<tr>
<th>Day of treatment</th>
<th>Dose of Lunsumio</th>
<th>Volume of Lunsumio in sodium chloride 9 mg/mL (0.9%) or 4.5 mg/mL (0.45%) solution for injection</th>
<th>Size of infusion bag</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1 Day 1</td>
<td>1 mg</td>
<td>1 mL</td>
<td>50 mL or 100 mL</td>
</tr>
<tr>
<td>Day 8</td>
<td>2 mg</td>
<td>2 mL</td>
<td>50 mL or 100 mL</td>
</tr>
<tr>
<td>Day 15</td>
<td>60 mg</td>
<td>60 mL</td>
<td>100 mL or 250 mL</td>
</tr>
<tr>
<td>Cycle 2 Day 1</td>
<td>60 mg</td>
<td>60 mL</td>
<td>100 mL or 250 mL</td>
</tr>
<tr>
<td>Cycle 3 and beyond</td>
<td>Day 1</td>
<td>30 mg</td>
<td>100 mL or 250 mL</td>
</tr>
</tbody>
</table>

3. Gently mix the infusion bag by slowly inverting the bag. Do not shake.
4. Inspect the infusion bag for particulates and discard if present.
5. Apply the peel-off label from the leaflet to the infusion bag.

**Diluted solution**

The product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

**Peel-off label**

Peel and apply this label to the infusion bag.